PIM
FATE icon

Partner Investment Management’s Fate Therapeutics FATE Stock Holding History

Partner Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,899
Closed -$138K – 47
2019
Q3 		$138K Sell
8,899
-3,429
-28% -$65.7K 0.24% 60
2019
Q2 		$250K Buy
12,328
+4,456
+57% +$80.3K 0.27% 68
2019
Q1 		$138K Sell
7,872
-4,415
-36% -$69.7K 0.16% 76
2018
Q4 		$158K Sell
12,287
-100
-0.8% -$1.39K 0.2% 69
2018
Q3 		$202K Buy
+12,387
New +$146K 0.15% 96

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Partner Investment Management's FATE Position: Q4 2019 in Review

Partner Investment Management sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 8,899 shares — an estimated $138K sold.

Partner Investment Management first reported a position in FATE in Q3 2018 and held it in 5 quarters. The position peaked at $250K in Q2 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • Partner Investment Management reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Partner Investment Management sold 8,899 Fate Therapeutics shares in Q4 2019, an estimated $138K.
  • Partner Investment Management first reported a position in Fate Therapeutics in Q3 2018 and held it in 5 quarters.
  • Partner Investment Management's Fate Therapeutics position peaked at $250K in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.